Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SDRD2HTR1BHTR1DHTR1F
The experimentally established mechanism targets of Niacinamide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 1/20 | 0.65 |
| ▸ | F3 | P13726 | 1/20 | 0.65 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.65 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.65 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.65 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.65 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.65 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.65 |
| ▸ | SIRT4 | Q9Y6E7 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | APP | P05067 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.49 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.45 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Niacinamide SCHEMBL29011862 | 1.00 | F7 (0.65) | F7F3SARM1SIRT2SIRT6 | |
| Malic Acid SCHEMBL810935 | 0.88 | ALDH1A1 (0.66) | F7F3SARM1SIRT2SIRT6 | |
| Malic Acid SCHEMBL31380098 | 0.88 | ALDH1A1 (0.66) | F7F3SARM1SIRT2SIRT6 | |
| Malic Acid SCHEMBL28810369 | 0.85 | ALDH1A1 (0.49) | F7F3SARM1SIRT2SIRT6 | |
| Cadaverine Tartrate SCHEMBL29103712 | 0.83 | F7 (0.76) | F7F3SARM1SIRT2SIRT6 | |
| Cadaverine Tartrate SCHEMBL27679158 | 0.83 | F7 (0.76) | F7F3SARM1SIRT2SIRT6 | |
| Benzamide SCHEMBL27802023 | 0.82 | TSHR (0.59) | SMN1; SMN2TDP1 | |
| Niacinamide SCHEMBL675207 | 0.82 | F7 (0.96) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL74569 | 0.81 | F7 (0.73) | F7F3SARM1SIRT2SIRT6 | |
| Niacinamide SCHEMBL6698484 | 0.81 | F7 (0.73) | F7F3SARM1SIRT2SIRT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4514362-A1 | NICOTINAMIDE RIBOSIDE DOSAGE REGIMEN FOR TREATING PARKINSON'S DISEASE | VESTLANDETS INNOVASJONSSELSKAP AS (VIS) (NO) | 2025-03-05 | — | — | EP | claimed |
| CN-117598953-A | Whitening composition and preparation method and application thereof | 广东博禧高新科技有限公司 | 2024-02-27 | — | — | CN | claimed |
| WO-2023209010-A1 | NICOTINAMIDE RIBOSIDE DOSAGE REGIMEN FOR TREATING PARKINSON'S DISEASE | VESTLANDETS INNOVASJONSSELSKAP AS (VIS) (NO) | 2023-11-02 | — | — | WO | claimed |
| CN-116966119-A | Green natural supermolecule liposome emulsion and preparation method thereof | 北京理工大学重庆创新中心 | 2023-10-31 | — | — | CN | claimed |
| CN-116236410-A | Ionic liquid cosmetic peptide stock solution and preparation method and application thereof | 武汉绿合医药科技有限公司 | 2023-06-09 | — | — | CN | claimed |
| US-20060147508-A1 | Concurrent Enhancement of Skin Penetration of Organic Base Active Agents and Organic Hydroxy Acid Active Agents as Their Ion-Pair Complexes | BIODERM RESEARCH (US) | 2006-07-06 | — | — | US | claimed |
| US-20040228884-A1 | Ion-pair delivery system for cosmetic and pharmaceutical compositions | GUPTA SHYAM K (US) | 2004-11-18 | — | — | US | claimed |
| US-20040156873-A1 | Topically Bioavailable Acne and Rosacea Treatment Compositions | GUPTA SHYAM K (US) | 2004-08-12 | — | — | US | claimed |
| US-20040092482-A1 | Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions | GUPTA SHYAM K (US) | 2004-05-13 | — | — | US | claimed |
| US-20040081672-A1 | Niacinamide, niacin, and niacin esters based delivery systems for treating topical disorders of skin and skin aging | GUPTA SHYAM K (US) | 2004-04-29 | — | — | US | claimed |
| US-20250275995-A1 | NICOTINAMIDE RIBOSIDE DOSAGE REGIMEN FOR TREATING PARKINSON'S DISEASE | VESTLANDETS INNOVASJONSSELSKAP AS (VIS) (NO) | 2025-09-04 | — | — | US | disclosed |
| EP-4514362-A1 | NICOTINAMIDE RIBOSIDE DOSAGE REGIMEN FOR TREATING PARKINSON'S DISEASE | VESTLANDETS INNOVASJONSSELSKAP AS (VIS) (NO) | 2025-03-05 | — | — | EP | disclosed |
| CN-118302145-A | Cosmetic water-in-oil emulsion comprising a specific water-soluble UV screening agent, a base, a volatile oil, a hydrophobic film-forming polymer, a polyoxyalkylene-alkylated linear polydimethylsiloxane and vitamin B3 | 莱雅公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-4370092-A2 | A NON-THERAPEUTIC COSMETIC METHOD FOR REDUCING WRINKLES ON A SKIN SURFACE | L'OREAL (FR) | 2024-05-22 | — | — | EP | disclosed |
| CN-117598953-A | Whitening composition and preparation method and application thereof | 广东博禧高新科技有限公司 | 2024-02-27 | — | — | CN | disclosed |
| WO-2005123101-A1 | BLACKBERRY EXTRACT | SYMRISE GMBH & CO. KG (DE) | 2005-12-29 | — | — | WO | disclosed |
| US-20050037038-A1 | Cosmetic Dermabrasion Treatment System | GUPTA SHYAM K (US) | 2005-02-17 | — | — | US | disclosed |
| US-20040228884-A1 | Ion-pair delivery system for cosmetic and pharmaceutical compositions | GUPTA SHYAM K (US) | 2004-11-18 | — | — | US | disclosed |
| US-20040092482-A1 | Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions | GUPTA SHYAM K (US) | 2004-05-13 | — | — | US | disclosed |
| US-20040081672-A1 | Niacinamide, niacin, and niacin esters based delivery systems for treating topical disorders of skin and skin aging | GUPTA SHYAM K (US) | 2004-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040092482-A1 | Hydroxy acids based delivery systems for skin resurfacing and anti-aging compositions | CUTA, HIRA, HARS1 | F7 3378/4885F3 4156/4885SARM1 4221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.